Venclexta (venetoclax)

White arrow on a road pointing to the rising sun
Research

Amphista's targeted glue sticks the landing in early AML test

Amphista has reported preclinical leukemia data on its protein degrader, positioning the biotech to target a 2026 start date for a phase 1 trial.
Nick Paul Taylor Dec 8, 2025 7:40am
A series of dice with a bag on them illustrating cost cuts

Ryvu loses 30% of staff in focus on ph. 3 blood cancer trials

Feb 25, 2025 10:00am